None listed
Conditions
Interventions
Vemurafenib 240mg coated tablets, oral administration. Treatment will continue until progression of disease or as long as the patient is deriving clinical benefit, as judged by the investigator (case-
Sponsors
F. HOFFMANN-LA ROCHE LTD.,
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Disease-Specific Inclusion Criteria: 1. BRAFV600 mutation-positive malignancy 2. Prior eligibility for and on study treatment from an antecedent vemurafenib protocol 3. Ability to begin treatment in the extension (rollover) protocol within 15 days following the last day of the study in the antecedent protocol General Inclusion Criteria: 1. Signed Informed Consent Form(s) 2. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use two adequate methods of contraception including at least one method with a failure rate of < 1% per year during the course of this study and for at least 6 months after completion of study treatment. • Females of childbearing potential are defined as sexually mature women without prior hysterectomy who have had any evidence of menses in the past 12 months. In order to be considered not of childbearing potential, amenorrhea for a period of 12 months or longer must have occurred in the absence of chemotherapy, anti-estrogen therapy, or ovarian suppression. • Effective forms of contraception include surgical sterilization, a reliable barrier method with spermicide, birth control pills, contraceptive hormone implants, or vasectomized partner. 3. Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential; women of non-childbearing potential may be included if they are either surgically sterile or have been naturally menopausal for < 1year. Women of non-childbearing potential need not undergo the pregnancy test.
Exclusion criteria
Exclusion criteria: 1. Adverse event requiring discontinuation of vemurafenib in the antecedent protocol 2. Progressive disease during the antecedent protocol. If approval to treat beyond progression was already given in the antecedent protocol, the patient may roll over into the current protocol without sponsor approval. Under special circumstances, when it is felt that the patient may clinically benefit from continued therapy with vemurafenib, enrollment into this protocol and dosing beyond progression may considered, if it is judged by the investigator, in consultation with the Sponsor, to be in the best interest of the patient. All such cases will require approval of the Sponsor before enrolling the patient into this protocol. 3. Meeting any of the following exclusion criterion of the antecedent study at the time the patient is considered for the extension (rollover) study: • Current, recent (within 28 days prior to Day 1), or planned use of any antitumor therapy outside of this study • Any other serious concomitant medical condition that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient’s ability to participate in the study • History of malabsorption or other clinically significant metabolic dysfunction • History of clinically significant cardiac or pulmonary dysfunction as specified in antecedent study
Countries
Argentina, Australia, Belarus, Bosnial and Herzegovina, Brazil, Canada, Croatia, Cyprus, Egypt, Finland, Germany, Greece, Hungary, Israel, Korea South, Netherlands, New Zealand, Portugal, Romania, Russian Federation, Spain, Turkey, United Kindgdom, United States
Contacts
Public ContactGabriela Celina Loyola
IQVIA RDS Peru S.R.L
Outcome results
None listed